Medicare has made headlines by announcing negotiated price cuts for 15 high-priced prescription drugs, including popular medications such as Ozempic and Wegovy. The Centers for Medicare & Medicaid Services (CMS) revealed that these negotiations are set to result in substantial savings, with discounts of up to 71% being reported. The implications of these cuts are significant, as they aim to lower costs for seniors and demonstrate the effectiveness of Medicare drug price negotiations. While the Trump administration previously touted $12 billion in savings through similar negotiations, ongoing legislative efforts aim to extend price caps beyond Medicare to include commercial insurance. The discussions surrounding these price reductions further highlight the ongoing debate over drug accessibility and affordability in the U.S., as various political factions, including House Democrats, push for expanded negotiation powers.